skb500
Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Phase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 65/ 100
Competitive context
290 Active assets in the Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benmelstobart Yayi He | Phase 4 | A |
Adebelimab Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | BBB |
vx-970 National Cancer Institute (NCI) | Phase 2 | BBB |
Veliparib Central European Society for Anticancer Drug Research | Phase 2 | BB |
hs-20093 Shanghai Hansoh Biomedical Co., Ltd | Phase 3 | BB |
View all 50 →
Same molecule, other indications
skb500 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →